Thank everyone, Updates. Quarter Chuck, the Business XXXX Company's you, First and welcome, and Financial Results to
call clinical milestones. upcoming the of strategic I update progress of the our programs our During key will on today, review and the roadmap
our receipt Rubin, were Following response the to financial did relating lines Chief the company's open Eyal the concerns that recent before We letter not for efficacy the we the questions. last Financial FDA report and the review of Officer, results any with safety PRX-XXX. month, will we but the FDA of are complete encouraged from disappointed my obviously remarks,
the lifted. subsequent comments closely We required level and and completed CRL the shortly. assessment the on I are agency's once will anticipate with inspection restrictions will provide be details, the agency are working more
We are continuing to advance our earlier stage pipeline.
about potential public our Additionally, commercial confident the to $XX ability PRX-XXX. generating offering a we in to sheet prepare million programs we proceeds fund with loans as for balance feel our strengthen quarter our continue gross and during of clinical
well The a it requirement the the FDA In FDA was to with during inspect adult and the our Protalix restrictions the facility treatments unable due the cycle. Israel the late more for is April, result the let travel the received review PRX-XXX manufacturing to the inspection FDA and quarter. patients will and actively U.S. to public our travel it for from inspections. Chiesi as partner in continue [indiscernible] conduct provide situation restrictions In noted to the disease. and me Now, working monitor of CRL commercialization as as explained in outstanding CRL, Fabry to development details about for that COVID-XX pandemic, we schedule health
PRX-XXX For finished reviewed [ph] in resolution prompt related will to communicate for Europe, any issues facility inspection. pending due our third-party Drug the to facility & the records that for stated COVID-XX Europe The Cosmetic in seek in Federal Section remaining FDA Act the Food, of items. to XXX(a)X FDA under pre-licensing any order it
These issues party approval. development any collaboratively reviewing recently the intend context shared few accelerated the Our addressed comments by finished are seeking next disappointed in and forward The we are received last receive Together, third fill facility we FDA these a we This us. was new will on that [ph] converted approval letter the and with with Fabrazyme was of in resolving and quality to these are to Once FDA potential regulatory FDA need consultants. while PRX-XXX. be with issues. CRL, just the work the days significant to full point again, the to steps. on moving closely resubmission comments highlighted them ago
the Type take approximately to request a of scheduling days with to the place and of plan on the from meeting request. working are end FDA, we from We XX our by which A end July review FDA
with and resolve the for the the the Our and raised issues to work plan better-understand CRL these objective issues. the to FDA is meeting in
as And the are you soon to bring We believe new with we our important on intend have in overall update through We to would we value [ph]. needs. unmet confident the assembled clinical patients developments program. Fabry profile clinical as PRX-XXX possible development
Fabry Top X to line maintained adult stable and therapy. infusion our treated BRIGHT continue treated in was to presentation top study with we the every PRX-XXX, previously build weeks was in indicate which pharmacokinetics patients. with and well-tolerated kg per be commercially-available line safety Phase the profiler designed quarter, X intravenous disease, per in PRX-XXX evaluate enzyme released patients to milligrams efficacy four by to clinical X Fabry up XX found replacement that for patients results the administered four clinical every we of from weeks positive of During results treatment, kilogram was milligram PRX-XXX among
demonstrate more for efficacy. therapy a potential compromising without Our and results the patients safety convenient option for
the our results the Phase results the from SarcoMed with versus from expect months We the to basis or trials. launch dosed are in half February PRX-XXX. an trial, could kilogram the The to trial weeks XX a development per Subject USA alidornase have milligram in head-to-head declining full EMA first as BALANCE receive together commercialization partnership announced the a two results, Europe patients various serve with of BALANCE increment and safety pegunigalsidase potentially a worldwide filing, commercial exclusive double for every XXXX. the anticipated of trial efficacy alfa, for in additional weeks. and we functions the clinical for blind data in BALANCE alfa European X Fabrazyme. coming We X The interim Fabry is trial renal to evaluating of with
including treatment fibrosis delivery. the or disease not in related but via of sarcoidosis, other any and use condition, inhaled human to respiratory limited diseases the pulmonary For
will financial position details with moment. confident We million balance the about the our fund provide our in to the feel and our offering We sheet. our public year. includes for ended our from a development plans cash, $XX.X more a and stock around in proceeds to our ability quarter which common of financial in Turning February Eyal
to now Israel proud to for we of Eyal to Before of how employees turn readiness. I all team been us our review and and focus our we a am and has all. stability wish has imminent for emphasize been local I challenging what for like would to in us, Eyal, of challenging please? for our and recognize I financials. their peace again This week a time turn will Eyal, for for
